CRP

Supporting Antimicrobial Stewardship Using Point of Care CRP Testing, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
星期三, 十一月 9, 2022
Antimicrobial stewardship, POCT, Lancet, CRP, C-reactive protein, Industry, Patient, MD, Infection, Etten-Leur, Death, Associate, Food, Medical Affairs Bureau, Government, AMR, Doctor of Philosophy, Wellcome Trust, Association, Degenerative disease, Research, WHO, Risk, General practice, Medical device, Medicine, Pharmaceutical industry

TORONTO, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The World Antimicrobial Awareness Week, held from November 18 to 24, 2022, calls attention to the high priority global issue¹,² of antimicrobial resistance (AMR). We know that 80% of acute respiratory tract infections in general practice are caused by viral infection where the use of antibiotics is of little to no benefit³. There is a direct relationship between the prescribing of antimicrobials and the development of AMR4, making infections harder to treat and increasing the risk of disease spread, severe illness and death⁴. Tackling AMR requires a multi-faceted approach and research has shown how incorporating CRP (C-reactive protein) testing into clinical practice may help to limit antibiotic use to only those patients with severe bacterial infections and thereby support antimicrobial stewardship.

Key Points: 
  • In this free webinar, learn about the causes of antimicrobial resistance (AMR) and why antibiotic stewardship is of critical importance.
  • Attendees will learn about the benefits of point of care CRP (C-reactive protein) testing in primary and community-based care.
  • Register for this webinar to learn about supporting antimicrobial stewardship using point of care CRP testing and changing antibiotic prescribing behaviours in primary care settings.
  • For more information, or to register for this event, visit Supporting Antimicrobial Stewardship Using Point of Care CRP Testing .

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

Retrieved on: 
星期三, 十一月 9, 2022
Union, Lung, Systemic scleroderma, Serum, Skin, Extracellular matrix, CRP, Risk, Liver, CXCL10, Fibrosis, Hospital, Nature, SEC, Biomarker, Private Securities Litigation Reform Act, Pneumonia, TEL, Population, Administration, Cirrhosis, C-reactive protein, Trial of the century, Conditional sentence, Treatment, CXCL9, Forward-looking statement, Inflammation, COVID-19, Scleroderma, PSC, Communication, CCL24, Conference, Nasdaq, Primary sclerosing cholangitis, Marketing, Research, Therapy, Safety, Adult, CMMB, Cytokine, Pharmaceutical industry, Silviculture, Patient

TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, announced that clinical data presented today showed that CM-101 was safe and well-tolerated and achieved reductions in biomarkers associated with lung inflammation and fibrogenesis in a clinical study in patients hospitalized with COVID-19-derived lung injury. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis (PSC) and systemic sclerosis (SSc).

Key Points: 
  • The presentation, Treatment with CM-101 Reduced Inflammatory & Fibrotic Biomarkers in Patients with COVID-19-Derived Lung Damage, was discussed by Chemomab co-founder and Chief Scientific Officer Dr. Adi Mor at the Union World Conference on Lung Health 2022.
  • The objective of the study was to evaluate the drug's safety and activity in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
  • The open label, single arm trial enrolled 16 adult COVID-19 patients with severe respiratory involvement.
  • CM-101 exposures and target engagement profiles were similar to what Chemomab researchers have seen in previous clinical studies of CM-101.

ProciseDx Announces FDA Clearance of ProciseDx instrument and C Reactive Protein (CRP) Assay

Retrieved on: 
星期二, 十一月 8, 2022
Workflow, CE marking, Serum, TDM, CRP, Inflammatory bowel disease, FDA, Patient, Blood, Membrane protein, Adalimumab, Therapeutic drug monitoring, SAN, IBD, De novo, Mimms, Point of care, GI, Gastroenterology, IVD, Chairperson, Commercialization, Health, Infliximab, Technology, Medical imaging, Pharmaceutical industry, Medical device, Risk management, COVID-19

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- ProciseDx Inc. announces FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test. Procise CRP gives quantitative determination of CRP levels in patient serum in less than 5 minutes. ProciseDx expects FDA clearances of additional tests in 2023.

Key Points: 
  • SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- ProciseDx Inc. announces FDA clearance of its ProciseDx instrument and C reactive Protein (CRP) test.
  • A first FDA Clearance is an important validation of ProciseDx's new technology.
  • For the US market, ProciseDx has submitted De Novo applications to the FDA for two TDM tests.
  • "FDA Clearance is major achievement for the ProciseDx team Biosynex has supported the development and commercialization of the ProicseDx platform.

Nanomix Enters into Multi-Country Distribution Agreement for the eLab System with Mast Group Limited

Retrieved on: 
星期五, 十一月 4, 2022
Public health, Company, Health care, Growth, Medication, Time, CE, SAN, C-reactive protein, Industry, Solution, GLOBE, Elab, POC, PCT, Sepsis, LAC, Point-of-care testing, Health, OTCQB, Infection, MHRA, Microbiology, U.S. Securities and Exchange Commission, Forward-looking statement, Molecular biology, Procalcitonin, Decision-making, Analyser, CRP, Technology, Pneumonia, Pleasure, Marketing, Security (finance), Diagnosis, United Kingdom, Medical device, Pharmaceutical industry

Mast will market and distribute the Nanmix eLabsystem in the United Kingdom, Germany, France, Ireland and South Africa.

Key Points: 
  • Mast will market and distribute the Nanmix eLabsystem in the United Kingdom, Germany, France, Ireland and South Africa.
  • John Hardesky, Chief Commercial Officer of Nanomix, stated, It has been a pleasure working with The Mast Group to bring this agreement to fruition.
  • The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.
  • Mast Group Ltd.offers its specialized product range through its own companies plus a global network of distributors.

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Retrieved on: 
星期二, 十月 25, 2022
IND, Epilepsy, Chest pain, NASDAQ, Fatigue, Profile, FDA, Hospital, Pericardium, Degenerative disease, Cancer, Myocarditis, C-reactive protein, Chronic pain, CEO, Food, CRDL, Patient, ARCHER, News, Cannabidiol, Research, Muscle tissue, Seizure, Heart transplantation, History, Company, Heart failure, Pericarditis, Safety, Disease, Prognosis, Inflammation, Cardiovascular disease, Program, Orphan, Food and Drug Administration, Risk, Heart, CRP, Therapy, Length of stay, Clinical trial, Death, TSX, NRS, Quality of life, COVID-19, Pharmaceutical industry

Discontinues LANCER Trial due to Lack of Eligible Patients for Recruitment

Key Points: 
  • Cardiol is currently advancing its Phase II ARCHER trial, designed to assess CardiolRx in acute myocarditis, an inflammatory condition of the heart muscle (myocardium).
  • Concurrent with the ARCHER trial, the Company is also undertaking a Phase II pilot study in recurrent pericarditis - a debilitating inflammatory heart disease.
  • Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases.
  • The Company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases.

Global C-Reactive Protein Testing Market Research Report 2022 with Competitive Profiles of Thermo Fisher Scientific, F Hoffmann-La Roche, Danaher, Quest Diagnostics, & Siemens Healthineers - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 24, 2022
Health, Biotechnology, Atherosclerosis, Risk, Glucose, Growth, Infection, Asia-Pacific, Smoking, Organization, C-reactive protein, Tissue, Inflammation, WHO, World, Acquisition, Obesity, Blood, Artery, CVD, Weight gain, American Heart Association, World Health Organization, Eating, CRP, Abcam, Cardiovascular disease, Degenerative disease, Death, Neonatal sepsis, Chronic obstructive pulmonary disease, Stroke, Dietary supplement, COPD, HB

The "C-Reactive Protein Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "C-Reactive Protein Testing Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the c-reactive protein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing cases of cardiovascular diseases (CVD) are expected to propel the growth of the c-reactive protein testing market.
  • Major companies operating in the c-reactive protein testing market are focused on providing technologically advanced solutions to strengthen their market position.

Nanomix Enters into Distribution Agreement for the eLab System with Diaclinic SpA in Chile

Retrieved on: 
星期四, 十月 20, 2022
SAN, LAC, Sepsis, Time, U.S. Securities and Exchange Commission, Health care, Growth, MHRA, PCT, Diagnosis, C-reactive protein, Republic, Spondyloarthropathy, Patient, Procalcitonin, Medication, Security (finance), Point-of-care testing, Company, Industry, OTCQB, Health, Elab, CRP, Analyser, CE, Decision-making, GLOBE, Forward-looking statement, Triage, POC, Medical device, Medical imaging, Pharmaceutical industry

We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system, stated Thomas Schlumpberger, Chief Executive Officer of Nanomix.

Key Points: 
  • We continue to expand our footprint internationally and gain strategic regions due to the unique benefits of the eLab system, stated Thomas Schlumpberger, Chief Executive Officer of Nanomix.
  • In approximately 12 minutes, the eLab system can provide healthcare professionals accurate and quantitative results without sending samples to a central lab.
  • Additionally, first responders and other healthcare providers can use the eLab for quick, on-the-spot assessment and triage of patients no matter where they are.
  • The Nanmix eLab system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.

ACA Group Acquires Compliance Resource Partners

Retrieved on: 
星期三, 十月 19, 2022
Software, Finance, Consulting, Data Management, Professional Services, Technology, Fintech, Security, Solution, CRP, GRC, Company, Industry, Risk, Culture, Â, CEO, Compliance, Technology, Audit, Financial adviser

ACA Group , the leading provider of governance, risk, and compliance (GRC) solutions to clients in the financial services industry, today announced it has acquired Compliance Resource Partners, Inc. (CRP), a comprehensive provider of regulatory compliance serving the financial services community.

Key Points: 
  • ACA Group , the leading provider of governance, risk, and compliance (GRC) solutions to clients in the financial services industry, today announced it has acquired Compliance Resource Partners, Inc. (CRP), a comprehensive provider of regulatory compliance serving the financial services community.
  • Were thrilled to welcome the CRP team to ACA Group, as we continue to target companies with top talent, great client service, and well-established GRC offerings to bolster our own, said Shvetank Shah, CEO of ACA Group.
  • In a rapidly changing compliance-driven world, our clients will have access to a broader level of specialized expertise, paired with comprehensive regulatory technology across all areas of compliance, said Kimberly Collins, president at Compliance Resource Partners.
  • ACA Group (ACA) is the leading governance, risk, and compliance (GRC) advisor in financial services.

Columbia River Partners Announces Investment in TiniFiber

Retrieved on: 
星期一, 十月 17, 2022
Transport, Partner, Rest, CEO, UMB Financial Corporation, Mezzanine, LLC, Investment, SBIC, Lamar Hunt, Maximilian armour, Subpoena duces tecum, Industry, Enterprise Bank, SBA, Small business, Health, LSZH, McGuireWoods, Employment, Technology, CRP, Insurance, Small Business Administration, Information technology, FINRA, Fiber to the x, Security (finance), Financial services, Operation, EBITDA

SEATTLE, Oct. 17, 2022 /PRNewswire/ -- Columbia River Partners ("CRP") is proud to announce its investment in TiniFiber Holdings, LLC ("TiniFiber"), a fiber optic assembly and custom cable manufacturer.

Key Points: 
  • SEATTLE, Oct. 17, 2022 /PRNewswire/ -- Columbia River Partners ("CRP") is proud to announce its investment in TiniFiber Holdings, LLC ("TiniFiber"), a fiber optic assembly and custom cable manufacturer.
  • Columbia River Partners ("CRP") is a lower middle-market private equity firm focused on investments in business service, industrial, and information technology platforms in North America.
  • Nathan Chandrasekaran and Pooneet Goel, Partners at Columbia River Partners added, "Through Christian and Barry's leadership and dedication, TiniFiber grew from an idea into the most effective fiberoptic cable on the market today.
  • Columbia River Partners is a private equity firm focused on control investments in lower-middle market companies inNorth Americaacross the industrials, business services, and IT services sectors.

CONSTRUCTION RISK PARTNERS WELCOMES SARAH SHEPARD MCGUINNESS AS PARTNER

Retrieved on: 
星期四, 十月 6, 2022
Senior Consultant, Risk management, U.S. Securities and Exchange Commission, Insurance, McGuinness, Risk, SEC, Culture, Partner, Growth, Specialization, Retail loss prevention, Person, Annual report, NASDAQ, Security (finance), BRP, Multimedia, Partnership, Senior, Dream, SVP, Private Securities Litigation Reform Act, Wrap, Industry, CRP, Forward-looking statement, Real estate, Terminology, Ownership, Solution, View, Property management

BOSTON, Oct. 6, 2022 /PRNewswire/ --Construction Risk Partners (CRP), an indirect subsidiary of BRP Group, Inc. ("BRP Group" or the "Company") (NASDAQ: BRP), is pleased to announce the addition of Sarah Shepard McGuinness to the team as a Partner.

Key Points: 
  • BOSTON, Oct. 6, 2022 /PRNewswire/ --Construction Risk Partners (CRP), an indirect subsidiary of BRP Group, Inc. ("BRP Group" or the "Company") (NASDAQ: BRP), is pleased to announce the addition of Sarah Shepard McGuinness to the team as a Partner.
  • Mrs. Shepard McGuinness most recently served as Senior Vice President (SVP) at one of the nation's leading risk management consulting firms.
  • "Sarah's background and experience in managing risks associated with stabilized real estate assets adds an entirely new skill set to CRP and will allow present construction clients to remain clients of CRP post-construction and beyond," said Andy O'Brien, Partner, Construction Risk Partners.
  • Construction Risk Partners is the leading specialist broker for owners, developers, general contractors, engineers, and subcontractors that need to mitigate financial risks related to construction activity.